Group 1 - AbbVie plans to invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities in Illinois, integrating advanced manufacturing technologies with artificial intelligence [1][2] - The construction of these facilities is part of AbbVie's broader $100 billion commitment towards research and development in the U.S., with construction set to begin in spring 2026 and facilities expected to be operational by 2029 [2][4] - The company aims to strengthen its U.S. manufacturing capabilities to support innovation and enhance the delivery of next-generation medicines to patients, as stated by CEO Robert A. Michael [3][4] Group 2 - AbbVie is focused on discovering and developing targeted therapies for blood cancers and solid tumors, with a research pipeline that includes antibody-drug conjugates, targeted protein degradation, CAR-T cell therapies, and bispecific antibodies [5]

Core Insights - Novartis has commenced construction on a new global Biomedical Research center in San Diego, California, aimed at enhancing drug discovery capabilities and scientific infrastructure [1][3] - The facility, covering approximately 466,000 square feet, is expected to accommodate around 1,000 employees and will integrate with Novartis' global research sites [2][8] - The investment in this center is part of a broader USD 23 billion investment in the U.S. to expand research and development and advanced manufacturing capabilities [7][8] Company Developments - The new research center will focus on key therapeutic areas such as neuroscience and oncology, leveraging advanced technologies including AI and data analytics [3][6] - This facility will enhance Novartis' existing research efforts in San Diego, which has a legacy of over 25 years in research and development [4][5] - The center aims to foster collaboration with biotech, academic, and technology partners in the region, reinforcing San Diego's position as a leader in life sciences [4][5] Industry Impact - The establishment of the research center is expected to create high-quality jobs and contribute to the local economy by translating scientific breakthroughs into impactful medicines [4] - The facility will support end-to-end drug discovery across various disease areas and technology platforms, including gene and cell therapies, RNA-based therapies, and biologics [4][8] - Novartis' investment reflects a commitment to driving innovation and improving patient care on a global scale [5][6]